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ABSTRACT
Background: Inﬂiximab recently became the only biologic approved for
use in pediatric patients with severe active Crohn’s disease (CD).
Objectives: To estimate the cost-effectiveness of scheduled maintenance
treatment with inﬂiximab compared with standard care in children suf-
fering from severe active CD over 5 years from the UK National Health
Service perspective.
Methods: A Markov model was constructed to simulate the progression
of a hypothetical cohort of CD children through predeﬁned health states
on scheduled maintenance treatment with inﬂiximab (5 mg/kg). The data
to populate the model came from inﬂiximab trials from Targan et al.,
ACCENT I, and REACH. The health states included in the model were
remission, responding active disease, nonresponding active disease,
surgery, postsurgery remission, postsurgery complications, and death.
Standard care, comprising immunomodulators, and/or corticosteroids
were used as a comparator. The primary outcome was quality-adjusted
life-years (QALY) estimated using the EuroQol (EQ-5D) from a
European CD population. To account for the weight-based dosing of
inﬂiximab, a baseline patient weight of 40 kg that increased by 5 kg/year
up to 60 kg was used. The costs and outcomes were discounted at 3.5%
over a period of 5 years. Probabilistic sensitivity analyses were performed
by varying the inﬂiximab efﬁcacy estimates, costs, and utilities.
Results: The incremental cost-effectiveness ratio (ICER) for inﬂiximab
treatment was £14,607 compared with standard care. The sensitivity
analyses revealed the treatment effect of inﬂiximab to be the most inﬂu-
ential parameter with ICERs ranging from £10,480 to £37,017. Assuming
a willingness to pay of £30,000 per QALY, the probability of inﬂiximab
being cost-effective is 78.6%.
Conclusion: Scheduled maintenance treatment with inﬂiximab (5 mg/kg)
is likely to be a cost-effective treatment in children suffering from severe
active CD under an 8-week maintenance program.
Keywords: cost-effectiveness, Crohn’s disease, inﬂiximab, pediatric.
Introduction
Crohn’s disease (CD) is a common chronic inﬂammatory bowel
disorder of childhood and adolescence. Although the reported
incidence of CD is lower in children than in adults at around 0.2
to 8.5 per 100,000, there are indications that the incidence is
increasing [1–4]. CD signiﬁcantly impacts children, often result-
ing in growth retardation and psychosocial issues, such as social
isolation and behavioral problems. Children with CD also have a
higher prevalence of psychiatric disorders, such as depression
and anxiety, compared with healthy controls or children with
other chronic conditions such as type-I diabetes [4].
The ﬁnancial impact of adult CD has been reported in a study
from the UK, which suggested that hospital admissions account
for 75% of the total costs of CD, with mean costs over 6 months
nearing £7000 for an adult hospitalized patient and £516 for an
adult outpatient [5]. The ﬁndings of this study were consistent
with research from Sweden and the United States reporting sig-
niﬁcant hospitalization costs [6,7].
Although, no other study has estimated this burden speciﬁ-
cally in children, it is likely to be comparable to adults. Inﬂix-
imab reduces this burden as observed in a retrospective study of
205 patients across seven centers in the UK. The study reported
signiﬁcant reductions in mean costs in the range of £138 per
patient in 6 months post-inﬂiximab compared with 6 months
pre-inﬂiximab [8]. Nevertheless, the treatment cost of inﬂiximab
remains high and there is a need to demonstrate its value in the
CD treatment pathway.
The inﬂiximab randomized controlled trial, REACH, demon-
strated that 88% of moderate to severe CD children achieved
clinical response after inﬂiximab induction treatment (at weeks
0, 2, and 6) and more than half of these patients achieved and
maintained a clinical remission on continued dosing regimen for
8 weeks up to 1 year [9]. Inﬂiximab has also been recommended
as an alternative treatment for pediatric patients with severe
active CD (Harvey Bradshaw index [HBI] >8, CD activity index
[CDAI] >300) who are refractory to or intolerant of steroids and
immunosuppression, and ineligible for surgery by the European
Crohn’s and Colitis Organisation [10–12].
This economic analysis was performed to assess the cost-
effectiveness of inﬂiximab scheduled maintenance treatment,
which is often labeled as expensive, compared with standard care
in pediatric CD patients over 5 years from the UK National
Health Service (NHS) perspective.
Methodology
Patient Population and Model Structure
The economic analysis was carried out in a hypothetical cohort
of children aged 6 years to 17 years with moderate to severe
active luminal CD, presenting with a pediatric CDAI (PCDAI)
score of 30 at baseline [13]. As per the REACH trial popula-
tion, the mean age assumed was 13 years (SD 2.5) and the mean
patient weight was 43.8 kg (SD 14.6). On average, these children
were suffering from CD for 2 years with a mean PCDAI score of
41.2 (SD 8.3). About one-third (34.9%) of the children were
using corticosteroids at the time of starting inﬂiximab treatment
[9].
A Markov model was used to simulate the disease progres-
sion and track associated costs and outcomes over 5 years of
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treatment. The disease activity was characterized using CDAI
instead of PCDAI to facilitate inclusion of adult CD estimates.
An overview of the model is presented in Figure 1. The disease
severity was characterized by two discrete “on-treatment” health
states, namely, remission (CDAI 150) and responding active
disease (CDAI >150). For children classiﬁed as nonresponders or
discontinuers, the disease severity was characterized by the “off-
treatment” health state of nonresponding active. The model also
included a total of three additional health states—surgery, post-
surgery remission, and postsurgery complications, as well as an
absorbing health state of death.
The cycle length used in the model was selected to facilitate
transfer of efﬁcacy estimates from clinical trial to inﬂiximab
dosing regimen. Therefore, the ﬁrst cycle was 2 weeks (week
0–2), followed by an 8-week, and a 20-week cycle (weeks 2–10
and 10–30). The cycle length thereafter was 24 weeks.
All children started in the responding active health state. At
the end of the ﬁrst cycle of 2 weeks and each subsequent model
cycle, children could either remain in the responding active
health state or move to a different health state depending on the
response. Responders achieving remission (CDAI 150) moved
to remission, whereas those not achieving remission remained in
the responding active health state. A response was deﬁned as 70
or more point reduction in the CDAI score from baseline and at
least a 25% reduction in the total score [14]. Nonresponders at
week 2, responders losing response in subsequent cycles, or
patients choosing to discontinue treatment moved to the nonre-
sponding active state. Nonresponders were switched to standard
care and could not return to inﬂiximab treatment.
Children in the responding active and the nonresponding
active health states could transition to surgery, which was an
outcome of disease progression. The surgery state included sur-
gical procedure and the postsurgical recovery included the asso-
ciated hospitalization. In the subsequent model cycles, children
could transition between surgery and the two postsurgery health
states. These transitions are outlined in Figure 1. Because of
unavailability of any evidence of inﬂiximab re-treatment efﬁcacy
on inﬂiximab failures, children with a recurrence of CD were not
offered inﬂiximab treatment. Patients in surgery and any of the
postsurgery health states could not receive any biologic treatment
for their CD but could receive treatment for their postsurgery
complications.
Treatment Interventions and Transition Probabilities
The treatment interventions modeled and compared included an
infusion at week 0 of either inﬂiximab 5 mg/kg (inﬂiximab sche-
duled maintenance) or placebo (standard care), followed by
repeated infusions for responders at week 2, week 6, and every 8
weeks thereafter.
Table 1 displays the sources of transition probabilities.
Because the REACH trial [9] did not include a placebo treatment
arm, data from the two adult studies of inﬂiximab Targan et al.
[15] and ACCENT I [14] were used to estimate the transition
probabilities. The transitions in the individual model cycles were
estimated using patient-level data from the clinical trials men-
tioned above. The remission and response rates used to estimate
these transition probabilities are displayed in Figure 2a.
The transition probabilities for the surgery and the postsur-
gical states were obtained from literature. The probability of
surgery was based on an average surgery rate of 64% in 10 years
obtained from a retrospective database study of 641 adult CD
patients [16]. In absence of any details on varying risk over time,
our analysis assumed a constant risk of surgery. The estimated
probabilities of postsurgery complications were based on a
cohort control study by Marchal and others, which compared
postsurgery complications with and without inﬂiximab [17]. The
authors concluded that inﬂiximab treatment did not have any
signiﬁcant impact on the frequency of postsurgery complications.
Therefore, a complication rate of 20.5% estimated as a weighted
average of complications observed in the comparative treatment
arms was used [17]. Reports in the published literature were used
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Figure 1 Markov model for moderate to severe pediatric Crohn’s disease.
Table 1 Use of trial data to derive efﬁcacy estimates
Treatment Weeks 0–2 Weeks 3–54
Inﬂiximab Targan et al. [15] (inﬂiximab) REACH [13] (inﬂiximab)
Standard care Targan et al. [15] (Placebo) ACCENT I [14] (placebo)
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to estimate the recurrence rates of 15.6% at 1 year in adult
patients with severe active luminal CD and the repeat surgery
rate of 16.7% at 1 year [18]. In absence of speciﬁc estimates in
pediatric patients, the rates of surgery, postsurgery outcomes,
and CD recurrence were assumed to be identical to the adult
patients. It was assumed that the survival rates in pediatric CD
were comparable to the survival in the general population [19]
after adjustment on age and sex and, the standardized mortality
ratio from all health states to death was 1.
Time Horizon
The efﬁcacy observed in the 54-week trial period was extrapo-
lated up to 5 years in the base-case analysis. These extrapolations
were based on the transitions observed in the last treatment cycle
(week 46–54) of the REACH trial. The last cycle transitions were
selected for extrapolation to negate the additional beneﬁcial
effect of induction dose in the treatment regimen. A 5-year time
horizon was assumed to be sufﬁcient to capture all the relevant
costs and effects of inﬂiximab in pediatric CD. Other scenarios,
including a 1-year and lifetime treatment, were explored in the
sensitivity analyses.
Costs
The perspective adopted on the costs was that of the NHS in
England and Wales. The reference year for the costs was 2006 to
2007.
The inﬂiximab treatment cost was broken down into its
acquisition costs and administration cost. The acquisition cost of
inﬂiximab was calculated using a baseline patient weight of
40 kg for an average 13-year-old patient at the beginning of the
analysis and gradually increased it up to 60 kg (5 kg/year) during
the follow-up period such that the average patient weight was
60 kg at adulthood. The drug administration cost of £96 per
infusion was used, which incorporated all tests, assessments, and
stafﬁng costs associated with the infusion [20]. This resulted in a
total cost per infusion of inﬂiximab in the range of £935.24
(40 kg) to £1354.86 (60 kg).
The concomitant medication use was estimated using all
patient baseline information in the REACH trial [9]. In our
model, we assumed that throughout the analysis period, patients
in presurgery health states maintained their baseline medication
use except corticosteroids as observed in the REACH trial. A
linear reduction in corticosteroid use, however, was assumed
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Figure 2 (a) Efﬁcacy estimates in base-case. (b)
Efﬁcacy estimates in scenario B. IFX, inﬂiximab;
S. care, standard care.
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such that patients achieving and maintaining remission were
assumed to be corticosteroid free by week 54. The proportion of
children discontinuing active treatment due to serious adverse
events was estimated using the REACH trial [9]. The model did
not explicitly account for the costs of adverse events. Potential
costs associated with infusion-related adverse events such as
infusion reactions, headache, dizziness, nausea, injection site
reaction, ﬂushing chest pain, dyspnea, and pruritus were consid-
ered to be incorporated in the administration cost. Serious
adverse events, related either to inﬂiximab or other medications
for CD, such as corticosteroids or immunomodulators, were
assumed to be included as part of the hospitalization costs.
The estimated average cost per surgical intervention was
£4190 based on the data published in the National Schedule of
Reference Costs (NSRC) for 2006 to 2007 (Table 2) [21]. This
was an average cost, taking into account elective and nonelective
admissions, with or without complications. The treatment-
related hospitalization and other assessments were estimated
using the study by Jewell and others [8], whereas the individual
health state costs were estimated using post hoc analysis of
ACCENT I [22]. This study by Lichtenstein and others reported
a 5.57-fold reduction in hospitalization for patients in remission
and a threefold reduction in hospitalization for responders com-
pared with nonresponders.
No published estimates were available for postsurgery health
states. Therefore, the resource use such as diagnostic tests, sur-
gical procedures, and hospitalizations associated with postsur-
gery remission and postsurgery complications was estimated by a
panel of UK gastroenterologists using the Delphi method. Each
panel member estimated the resource use independently, and
values used in the economic model were averages of individual
estimates. Individual health states were costed using NSRC for
2006 to 2007 [21].
Outcomes
The primary effectiveness measure used in these analyses was
quality-adjusted life-years (QALYs). Because of lack of available
data, the model did not account for any effect of inﬂiximab on
survival.
Once again, because of the lack of pediatric data, the health
state preference values were adapted from a study in adult CD
patients. A data set provided by Dr. Casellas, consisting of 201
adult Spanish moderate to severe CD patients from a published
study [23], formed the basis for the estimates used in this analy-
sis. The patients’ EQ-5D responses were converted into the cor-
responding utilities using UK tariffs [24] and were attributed to
individual health states using HBI [6]. No utility for the nonre-
sponding active state was available from literature; therefore, a
utility decrement of 0.1 was assigned to this state on consultation
with a panel of UK gastroenterologists.
The preference values for the surgery and postsurgical health
states were estimated from a secondary care database of 41 adult
CD patients in the UK using EQ-5D [25]. The utility estimates
obtained immediately after surgery (<2 months) were used for the
health state of surgery and those obtained two or more months
after surgery were used for postsurgery remission. There were no
estimates available for patients in the postsurgery complications
state; therefore, a utility value equivalent to the nonresponding
active state was assigned to this state. This was based on the
assumption that a postsurgery complication would lead to signiﬁ-
cant hospitalization alongwith symptoms of infection, resulting in
an impaired quality of life (QoL). The utility estimates used for the
corresponding health states in both treatment alternatives were
identical. The treatment beneﬁt achieved by inﬂiximab was thus
reﬂected only in the difference between the transition probabilities
of treatment alternatives. Table 3 provides a summary of all utility
estimates employed in the economic evaluation.
Cost-Effectiveness Analyses
The primary cost-effectiveness measure was the incremental cost
per QALY gained. Costs and outcomes were discounted to
present values at 3.5% per annum [25]. Half-cycle correction
was applied to reﬂect the transitions occurring throughout each
model cycle [26]. Multiple one-way sensitivity analyses were
conducted by varying parameters such as patient age and weight,
time horizon, discounting rate, and the administration cost of
inﬂiximab. The uncertainty surrounding other important vari-
ables such as transition probabilities, costs, and health state
utilities was explored using probabilistic sensitivity analyses
(PSA) with 10,000 simulations. The uncertainty surrounding the
transition probabilities and the utility estimates was presented
using the beta distributions. The distributions for the utility
estimates were restricted to make sure that the resultant utilities
represent health states that were clinically meaningful. For
example, the resultant utility of a patient in active state had to be
lower than that of a patient in remission in all the simulations.
The resource use costs, because derived from NHS published cost
estimates, were subjected to normal distributions. The means and
standard deviations derived from data sources were used to
estimate the distribution parameters.
Table 2 Hospitalization and assessments
Resource
Published estimate of resource use (n = 205)* Cost per patient per cycle (24 weeks)
Unit cost (£) SourcePre-inﬂiximab Post-inﬂiximab Standard care (£) Inﬂiximab (£)
Diagnostic procedures 162 63 356.04 138.45 488.11 TDC [21]
Examination under anesthetic 50 17 340.29 115.71 1511.52 TEI,TNEI [21]
Inpatient days 1435 342 1761.93 419.91 272.68 TEI,TNEI [21]
Outpatient visits 555 534 231.00 222.27 92.44 TCLFUSNFF [21]
Total 2689.29 896.34
*Resource use of 205 patients for 6 months [8].
TDC,day cases Health Resource Group (HRG) data; TEI,elective inpatient HRG data;TNEI,nonelective inpatient HRG data;TCLFUSFF,consultant-led follow-up attendance outpatient face to face.
Table 3 Utility estimates
Markov model health
state
Corresponding state
from the source Source
Utility
estimate
Remission Remission (HBI < 3) [23] 0.83
Active Active (HBI > 3) [23] 0.55
Nonresponding active Not available; assigned 0.55
Surgery Postsurgery (<2 months) [36] 0.73
Postsurgery remission Postsurgery (>2 months) [36] 0.67
Postsurgery complications Not available; assigned 0.55
Death — —
HBI, Harvey Bradshaw index (14).
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Alternate Scenarios
The following scenario analyses were conducted to address the
uncertainty around important parameters.
Scenario A: no treatment effect in the extrapolation phase. The
base case assumed continued efﬁcacy of inﬂiximab beyond the
trial period of 54 weeks. In scenario A, we explored no treatment
effect beyond 54 weeks, thus resulting in subsequent transitions
in the inﬂiximab arm to be identical to those in the standard care
treatment arm.
Scenario B: efﬁcacy of standard care. The base case assumed the
treatment effect of inﬂiximab in children to be identical to that
observed in adult patients. The uncertainty introduced by this
assumption was explored in scenario B. The cost-effectiveness
analysis in scenario B was entirely based on the REACH trial.
During the ﬁrst 10 weeks, the combined arm of the REACH trial
was assumed to represent both the standard care and inﬂiximab
treatments in our analysis. Following the randomization in
REACH at the 11th week, the 12-week and 8-week treatment
arms of the trial represented the standard care and inﬂiximab
treatment arms, respectively, in our analysis. Figure 2b displays
the efﬁcacy thus derived from the REACH trial and used in
scenario B.
All patients in the REACH trial received inﬂiximab through-
out 54 weeks. Therefore, the cost-effectiveness estimates in this
scenario are highly conservative with a minimum incremental
beneﬁt attributed to inﬂiximab.
Results
Cost-Effectiveness Analyses
In the base case, the scheduled maintenance therapy with inﬂix-
imab derived a mean additional 0.55 QALYs at a mean
additional cost of £8025 compared with standard care. The
incremental cost per QALY gained for inﬂiximab versus standard
care was £14,607. The corresponding incremental cost-
effectiveness ratios (ICERs) for inﬂiximab under scenarios A and
B were £18,768 and £37,017, respectively, as displayed in
Table 4.
Sensitivity Analyses
The results of the one-way sensitivity analyses demonstrated that
the ICERs remained in the range of £10,480 to £37,017 at 5
years (Table 5). The treatment effect of inﬂiximab (scenario B)
had the highest impact on ICER (£37,017). The impact of change
in the time horizon was less signiﬁcant, with the ICERs for 1 year
and lifetime horizons increasing to £18,624 and £21,223, respec-
tively. The PSA showed that the results were robust with a very
small proportion of simulations resulting in the southeast quad-
rant where inﬂiximab is dominated by standard care. At a
willingness to pay of £30,000 per QALY, the probability of
inﬂiximab scheduled maintenance treatment being cost-effective
was 78.6%. The corresponding probabilities under scenarios
A and B were 56.6% and 42.7%, respectively. The cost-
effectiveness acceptability curves for the base case and alternative
scenarios are shown in Figure 3.
Discussion
Scheduled maintenance treatment with inﬂiximab is effective in
achieving and maintaining remission in pediatric patients with
moderate to severe active CD [9]. Inﬂiximab trials in adults have
also shown its beneﬁt in reducing the surgeries and hospitaliza-
tions [14,27]. The purpose of this analysis was to assess the
cost-effectiveness of scheduled maintenance treatment with
inﬂiximab in pediatric active CD patients over a 5-year time
horizon.
Several published studies have estimated the cost-effectiveness
of inﬂiximab in adult CD patients [28–32]. To our knowledge, no
Table 4 Cost-effectiveness results for inﬂiximab scheduled maintenance versus standard care in pediatric active Crohn’s disease at 5 years
Scenario
Standard care
mean costs (£)
Inﬂiximab mean
costs (£)
Standard care
mean QALYs
Inﬂiximab
mean QALYs ICERs (£)
Base case 25,987 34,012 2.675 3.224 14,607
Scenario A 25,987 31,010 2.675 2.943 18,768
Scenario B 23,186 37,181 3.090 3.468 37,017
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Table 5 One-way sensitivity analysis*—inﬂiximab scheduled maintenance versus standard care in moderate to severe active Crohn’s disease
Parameter Base-case estimate Sensitivity estimate Cost/QALY† (£)
Patient weight 40 kg with progressive weight increase 40 kg (no weight increase) 10,480
50 kg (with vial sharing and no weight increase) 17,036
60 kg (no weight increase) 23,592
Time horizon 5 years 1 year 18,624
Lifetime 21,223
Discount rate Costs—3.5%
QALYs—3.5%
Cost and QALYs—1.5% 14,747
Cost—1.5% and QALYs—6% 12,935
Cost—6% and QALYs—1.5% 16,144
Cost and QALYs—6% 14,776
Health state utilities Increase by 10% 13,279
Decrease by 10% 16,230
Inﬂiximab administration cost £96.00 £124.00 15,482
*All results except “time horizon” assumes the time horizon of 5 years used in the base-case.
†Base-case: cost per QALY = £14,607.
QALY, quality-adjusted life-year.
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study has estimated it in children. Therefore, a direct comparison
of our results with the published estimates was not possible.
Three of the adult studies used Silverstein patient cohort as a
basis to estimate CD progression, whereas the other two used
patient cohorts eligible to receive biologic to build their model
frameworks. Because our study speciﬁcally focused on moderate
to severe patients eligible to receive inﬂiximab, we used the
model structure and treatment pathway previously used by
Lindsay and others [32]. This framework allowed inclusion of
patient-level data from inﬂiximab trials. The results of our base-
case analysis suggested that inﬂiximab is likely to be cost-
effective using the National Institute of Health and Clinical
Excellence (NICE) threshold of £20,000 to £30,000 per QALY
[25]. The ICERs in our study are lower than most of the pub-
lished estimates. This can be attributed to the observed higher
efﬁcacy in inﬂiximab trials and lower inﬂiximab costs in pediatric
patients. In the REACH trial, 63.5% patients maintained their
response and 55.8% patients maintained their remission by the
end of week 54 [9]. These numbers are signiﬁcantly higher com-
pared with the efﬁcacy observed in adult trials [14,27].
Although the base-case analysis resulted in an ICER within
the acceptable limit of the NICE, the ICER for scenario B was
above £30,000 per QALY. This scenario assumed minimum
incremental beneﬁt of inﬂiximab by assigning the active treat-
ment efﬁcacy to standard care treatment. The efﬁcacy thus
obtained for standard care treatment is signiﬁcantly higher than
that observed in adult trials [14] and unlikely to be observed in
clinical practice. We included this scenario in our analysis only to
present the most conservative estimate of incremental treatment
beneﬁt of inﬂiximab, which was the most important parameter
affecting ICER. Therefore, this result warrants a careful interpre-
tation of a worst-case scenario that is less likely to occur in a
clinical setting.
The choice of time horizon is an important consideration. CD
is a chronic condition, with more than half the patients under-
going a surgical intervention within 10 years of diagnosis [33].
This warranted analysis over a longer time horizon. Neverthe-
less, the efﬁcacy estimates were derived from the trials with short
treatment duration of 54 weeks. Therefore, in the base case, we
conducted analysis over a period of 5 years. A comparison of a
previous economic analysis with an observational study in adult
CD patients indicated that inﬂiximab was able to maintain its
efﬁcacy beyond the trial period, at least up to 4 years [32], and
thus supports our assumption. Nevertheless, no such comparable
data were available in children, and in the absence of any such
comparison, we may have overestimated inﬂiximab efﬁcacy in
the base case. This assumption was tested in scenario A. The
worst-case scenario A assumed no treatment effect beyond 54
weeks. The resultant inﬂiximab ICER of £18,768 further sup-
ported the efﬁcacy extrapolation in the base case.
The other important parameter affecting inﬂiximab efﬁcacy
was the choice of the data sources. We derived inﬂiximab efﬁcacy
based on two adult and a single pediatric trial. In the absence of
a placebo treatment arm in the REACH trial, we used placebo
data from an adult trial to estimate the efﬁcacy of the standard
care treatment arm in our analysis [14]. Such comparisons have
previously been drawn by regulatory authorities, including the
Food and Drug Administration, while granting license to inﬂix-
imab in the pediatric CD population [34]. We also explored other
possible approaches such as meta-regression but decided to
pursue a simplistic approach because of the heterogeneity in
inﬂiximab trials. This mix and match approach may have con-
tributed to uncertainty around inﬂiximab’s absolute and/or rela-
tive treatment effect and we explored that through the scenario
analyses and sensitivity analyses. In scenario B, we used efﬁcacy
estimates derived from the inﬂiximab 12-week dosing arm of
the REACH trial as proxy for standard care efﬁcacy estimates.
In the REACH trial, all patients received the full induction dose
and the responders were randomized at week 10. This meant that
in scenario B, the treatment effect of the induction dose was
identical in the inﬂiximab and standard care treatment arm. This
may have signiﬁcantly reduced the relative treatment effect of
inﬂiximab compared with standard care. In our sensitivity analy-
sis, only in this very conservative scenario, inﬂiximab ICER
exceeded the acceptable limit of cost-effectiveness.
The other important parameters affecting ICERs were health
state preferences and health state costs. Although the utility
distributions were adjusted to avoid counterintuitive results, a
small proportion of simulations (9.58%) in the PSA resulted in a
negative incremental QALY gain. This is contrary to the trial
evidence found in adult trials where inﬂiximab has been shown
to be effective in achieving and maintaining remission and asso-
ciated QoL beneﬁt. Again, this may be attributable to the mul-
tiple data sources used to derive efﬁcacy estimates as well as
health state preferences. The efﬁcacy estimates for a true stan-
dard care treatment were not available in the REACH trial.
Therefore, the efﬁcacy estimates from the adult trials were used.
The REACH trial also did not capture any QoL data. Health
state preferences were available from other published studies that
did not conform with the NICE’s analysis framework within
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which this analysis was conducted [28,31,35]. Therefore, we
used Casellas et al. patient cohort to derive presurgical utilities
and the Health Outcomes Data Repository (HODaR) data set to
derive postsurgery utilities [36]. This may have introduced uncer-
tainty resulting in negative QALY gains for active treatment.
We estimated the health state resource use from the Jewell
et al. study [8]. The study compared resource use among CD
patients before and after introduction of inﬂiximab in UK.
Similar estimates were also available from two other studies
[37,38]. We, however, preferred the Jewell et al. study as it rep-
resented UK clinical practice. The health states where resource
use was unavailable were estimated by a panel of UK gastroen-
terologists. These experts represented major gastroenterology
centers across UK and their estimates were subsequently pooled
to derive mean values used in the analysis. This simplistic
approach may have introduced uncertainty around the resource
use estimates, which was further explored in PSA. The PSA
showed that the predicted results of our model were comparable
to other published estimates. The study by Saro and others found
surgery rates of 9.8% and 4% 1 year prior and post-inﬂiximab
use. The corresponding rates in our model were 5.5% and 2.8%
at the end of the ﬁrst year [38]. In spite of this, the choice of
resource use estimates and the elicitation method used to derive
them where unavailable may have introduced uncertainty in the
results and this remains a limitation of this analysis.
In conclusion, the economic analysis demonstrated that
despite the uncertainty surrounding the results, inﬂiximab sched-
uled maintenance treatment is likely to be a cost-effective treat-
ment alternative for children suffering from moderate to severe
CD.
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